- Home
- NAKA vs PTGX Comparison
NAKA vs PTGX Comparison
Compare NAKA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAKA
- PTGX
- Stock Information
- Founded
- NAKA 2019
- PTGX 2006
- Country
- NAKA United States
- PTGX United States
- Employees
- NAKA N/A
- PTGX N/A
- Industry
- NAKA
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- NAKA
- PTGX Health Care
- Exchange
- NAKA Nasdaq
- PTGX Nasdaq
- Market Cap
- NAKA 347.4M
- PTGX 5.0B
- IPO Year
- NAKA 2024
- PTGX 2016
- Fundamental
- Price
- NAKA $0.71
- PTGX $85.55
- Analyst Decision
- NAKA Strong Buy
- PTGX Strong Buy
- Analyst Count
- NAKA 2
- PTGX 9
- Target Price
- NAKA $5.00
- PTGX $86.22
- AVG Volume (30 Days)
- NAKA 29.9M
- PTGX 998.7K
- Earning Date
- NAKA 11-05-2025
- PTGX 11-06-2025
- Dividend Yield
- NAKA N/A
- PTGX N/A
- EPS Growth
- NAKA N/A
- PTGX N/A
- EPS
- NAKA N/A
- PTGX 0.72
- Revenue
- NAKA $2,239,936.00
- PTGX $209,217,000.00
- Revenue This Year
- NAKA N/A
- PTGX N/A
- Revenue Next Year
- NAKA $2,755.19
- PTGX $140.23
- P/E Ratio
- NAKA N/A
- PTGX $115.56
- Revenue Growth
- NAKA N/A
- PTGX N/A
- 52 Week Low
- NAKA $0.65
- PTGX $33.31
- 52 Week High
- NAKA $34.77
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- NAKA 33.25
- PTGX 69.66
- Support Level
- NAKA $0.70
- PTGX $76.70
- Resistance Level
- NAKA $0.98
- PTGX $80.43
- Average True Range (ATR)
- NAKA 0.11
- PTGX 2.90
- MACD
- NAKA 0.12
- PTGX 0.28
- Stochastic Oscillator
- NAKA 4.85
- PTGX 96.58
About NAKA Kindly MD Inc. Common Stock
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.